Patient Population
Six hundred sixty-five patients with newly diagnosed high-risk
neuroblastoma were assessed for eligibility for COG ANBL0532 from
November 2007 through February 2012.3 Of these 665,
355 patients with newly diagnosed high-risk neuroblastoma who were
enrolled on COG ANBL0532, did not receive prior systemic therapy, did
not progress or die of toxicity during induction, and underwent
randomization to either single or tandem transplant were assessed for
inclusion in our Curie Score analysis (Supplemental FIGURE
S1) .3 Among the 355 randomized patients, 228 had
paired evaluable 123I-mIBG or131I-mIBG scans available at diagnosis and EOI.
Patients with mIBG non-avid disease (n=10) at diagnosis, International
Neuroblastoma Staging System (INSS) non-Stage 4 disease (n=19), and
those who did not undergo their assigned transplant (n=20) were excluded
from the final analysis. The resulting cohort of 179 patients, including
80 patients randomized to tandem and 99 randomized to single AHCT, was
examined. Written informed consent was obtained from all patients (or
legal guardians) before entry onto ANBL0532 and prior to consolidation
randomization. The trial was registered on ClinicalTrials.gov
(NCT00567567).